Search

U.S. cancer centers are rapidly trying to enroll patients in an early access program for daraxonrasib, a promising new pancreatic cancer drug from Revolution Medicines, following its FDA approval for expanded access after demonstrating a significant increase in survival rates in clinical trials. #PancreaticCancer #FDAApproval #CancerResearch #US #CA #NE

U.S. cancer centers are urgently enrolling patients in an early access program for Revolution Medicines' promising pancreatic cancer drug, daraxonrasib, following its recent FDA approval for expanded access, which comes after clinical trials showed it can double survival rates in advanced cases of the disease. #CancerResearch #FDAApproval #PancreaticCancer #US

U.S. cancer centers are urgently enrolling patients in an expanded access program for the promising pancreatic cancer drug daraxonrasib, which recently showed in clinical trials to significantly extend survival, while they await expected FDA approval amidst a surge of patient requests. #CancerResearch #FDAApproval #PancreaticCancer #US

U.S. cancer centers are rapidly trying to enroll patients in an early access program for Revolution Medicines' promising pancreatic cancer drug, daraxonrasib, following its FDA-approved expanded access due to its significant survival benefits demonstrated in clinical trials, amidst a surge of patient requests and logistical challenges in managing the program. #CancerResearch #FDAApproval #PancreaticCancer #US

U.S. cancer centers are rapidly enrolling patients in an early access program for daraxonrasib, a promising pancreatic cancer drug from Revolution Medicines, after the FDA approved the program following positive trial results that showed the drug doubled patient survival, while oncologists face logistical challenges in managing patient requests and navigating the approval process. #CancerResearch #FDAApproval #PancreaticCancer #US